Filing Details

Accession Number:
0001185185-15-003402
Form Type:
4/A
Zero Holdings:
No
Publication Time:
2015-12-31 13:53:35
Reporting Period:
2015-10-05
Filing Date:
2015-12-31
Accepted Time:
2015-12-31 13:53:35
Original Submission Date:
2015-10-07
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1530766 Biosig Technologies Inc. BSGM Electromedical & Electrotherapeutic Apparatus (3845) 264333375
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1449534 L Kenneth Londoner C/O Biosig Technologies, Inc.
8441 Wayzata Blvd., Suite 240
Minneapolis MN 55426
Yes No Yes No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock, $0.001 Par Value Per Share Acquisiton 2015-10-05 6,600 $1.55 430,750 No 4 P Direct
Common Stock, $0.001 Par Value Per Share Acquisiton 2015-10-06 10,494 $1.45 441,244 No 4 P Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 P Direct
No 4 P Direct
Footnotes
  1. This transaction was executed in multiple trades on October 5, 2015 at prices ranging from $1.50 to $1.58. The price reported reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer, upon request, full information regarding the number of securities purchased at each separate price.
  2. This transaction was executed in multiple trades on October 6, 2015 at prices ranging from $1.39 to $1.48. The price reported reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer, upon request, full information regarding the number of securities purchased at each separate price.
  3. Pursuant to Instruction 9(b) to Form 4, this amendment amends and restates only the lines items in Table I of the original filing reporting direct purchases by the reporting person to correct the amount of securities beneficially owned following the reported transactions.